Immunocore (NASDAQ: IMCR) R&D chief exits as company reshapes unit

Rhea-AI Filing Summary

Immunocore Holdings plc announced that David Berman has decided to resign as Head of Research & Development, effective February 27, 2026, to pursue another opportunity. The company states that his resignation is not due to any disagreement over operations, policies, or practices.

Immunocore does not plan to appoint a direct replacement for Dr. Berman and instead intends to streamline and leverage its existing R&D structure. This signals a leadership transition within the research organization while maintaining continuity through the current R&D framework.

Insights

Biotech leadership and governance analyst

Immunocore's Head of R&D is leaving, with R&D responsibilities redistributed internally.

The company reports that David Berman will resign as Head of Research & Development effective February 27, 2026 to pursue another opportunity. It explicitly notes that his decision is not due to disagreements about operations, policies, or practices, which helps frame this as a planned career move.

R&D leadership is critical for a company developing medicines, so the choice not to seek a direct replacement and instead "streamline and leverage" the existing R&D structure points to a more distributed leadership model. Actual impact will depend on how well the current team absorbs these responsibilities.

Investors may pay attention to future disclosures describing the streamlined R&D setup and any updates on Immunocore's development programs after February 27, 2026, to understand how the organization functions without a single Head of R&D role.

false000167192700-000000000016719272026-01-092026-01-090001671927imcr:AmericanDepositarySharesEachRepresentingOneOrdinaryShareNominalValue0002PerShareMember2026-01-092026-01-090001671927imcr:OrdinaryShareNominalValue0002PerShareMember2026-01-092026-01-09false000167192700-0000000GBAmerican Depositary Shares, each representing one ordinary share, nominal value 0.002 per shareOrdinary share, nominal value 0.002 per share*NASDAQNASDAQ00016719272026-01-272026-01-270001671927imcr:AmericanDepositarySharesEachRepresentingOneOrdinaryShareNominalValue0002PerShareMember2026-01-272026-01-270001671927imcr:OrdinaryShareNominalValue0002PerShareMember2026-01-272026-01-27

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 27, 2026

Immunocore Holdings plc

(Exact name of registrant as specified in its Charter)

England and Wales	001-39992	Not Applicable
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)

92 Park Drive, Milton Park Abingdon, Oxfordshire, United Kingdom		OX14 4RY
(Address of principal executive offices)		(Zip Code)

+44 1235 438600

(Registrant’s telephone number, including area code)

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
American Depositary Shares, each representing one ordinary share, nominal value £0.002 per share	IMCR	The Nasdaq Stock Market LLC
Ordinary share, nominal value £0.002 per share*	*	The Nasdaq Stock Market LLC

* Not for trading, but only in connection with the listing of the American Depositary Shares on The Nasdaq Stock Market LLC.

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On January 27, 2026, David Berman notified Immunocore Holdings plc (the “Company”) of his decision to resign as Head of Research & Development of the Company, effective as of February 27, 2026, in order to pursue another opportunity. Dr. Berman’s decision to resign was not the result of any disagreement between Dr. Berman and the Company or any matter relating to the Company’s operations, policies, or practices. The Company will not seek a direct replacement for Dr. Berman but will streamline and leverage its existing R&D structure.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	IMMUNOCORE HOLDINGS PLC
Dated: January 30, 2026	By:	/s/ Bahija Jallal, Ph.D.
		Name:	Bahija Jallal, Ph.D.
		Title:	Chief Executive Officer

FAQ

What did Immunocore (IMCR) disclose in its latest 8-K filing?

Immunocore disclosed that David Berman will resign as Head of Research & Development effective February 27, 2026. The company added that his decision was not due to any disagreement over operations, policies, or practices, and outlined plans to adjust its R&D structure.

Who is leaving Immunocore (IMCR) and what is their role?

David Berman is leaving Immunocore in his role as Head of Research & Development. According to the company, he notified Immunocore on January 27, 2026, of his decision to resign to pursue another opportunity, with his departure effective February 27, 2026.

When will Immunocore's Head of R&D resignation become effective?

David Berman’s resignation as Head of Research & Development will be effective February 27, 2026. He informed Immunocore of his decision on January 27, 2026, giving a one-month transition period before his departure from the R&D leadership role at the company.

Did Immunocore report any disagreements related to David Berman’s resignation?

No, Immunocore stated that David Berman’s decision to resign as Head of Research & Development was not the result of any disagreement with the company. This includes no disputes regarding its operations, policies, or practices, according to the language used in the filing.

Will Immunocore (IMCR) appoint a new Head of Research & Development?

Immunocore indicated it will not seek a direct replacement for David Berman as Head of Research & Development. Instead, the company plans to streamline and leverage its existing R&D structure, redistributing responsibilities within the current organizational framework.

How does Immunocore plan to manage R&D after David Berman’s departure?

Immunocore plans to manage R&D by streamlining and leveraging its existing R&D structure rather than appointing a new Head of R&D. This suggests responsibilities will be absorbed by the current team, maintaining research activities under a revised leadership arrangement.